Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
5-Amino-1MQ
Weight Management
Abarelix
Hormone Support
Acetyl Hexapeptide-3 (Argireline)
Cosmetic
Adipotide
Weight Management
Adrenomedullin
Healing & Recovery
Alexamorelin
Growth Hormone
Angiotensin (1-7)
Healing & Recovery
AOD-9604
Weight Management
Apelin-13
Healing & Recovery
ARA-290 (Cibinetide)
Healing & Recovery
Bestatin (Ubenimex)
Immune
BPC-157
Healing & Recovery
Buserelin
Hormone Support
Cagrilintide
Weight Management
CagriSema
Weight Management
Capromorelin
Growth Hormone
Cartalax
Anti-Aging
Cathelicidin (hCAP-18 / Synthetic Derivatives)
Immune
Cerebrolysin
Cognitive
Cerluten
Cognitive
Cetrorelix
Hormone Support
Chonluten
Immune
CJC-1295 (No DAC)
Growth Hormone
CJC-1295 with DAC
Growth Hormone
Cortexin
Cognitive
Crystagen
Immune
Daptomycin
Immune
Defensin (HBD-2)
Immune
Defensin (HBD-3)
Immune
Degarelix
Hormone Support
Dihexa
Cognitive
DSIP (Delta Sleep-Inducing Peptide)
Sleep & Recovery
Dulaglutide
Weight Management
Enalapril
Healing & Recovery
Epithalon
Anti-Aging
Exenatide
Weight Management
Fertirelin
Hormone Support
FOXO4-DRI
Anti-Aging
Ganirelix
Hormone Support
GHK-Cu (Copper Peptide)
Cosmetic
GHRH (1-29)
Growth Hormone
GHRP-2
Growth Hormone
GHRP-6 (Growth Hormone Releasing Peptide-6)
Growth Hormone
Glutathione
Anti-Aging
Gonadorelin (GnRH)
Hormone Support
Gramicidin
Immune
Hexarelin
Growth Hormone
Human Chorionic Gonadotropin (HCG)
Hormone Support
Human Growth Hormone (HGH)
Growth Hormone
IGF-1 LR3
Growth Hormone
Immunoxel (Dzherelo)
Immune
Imunofan
Immune
Intermedin (Adrenomedullin-2)
Healing & Recovery
Ipamorelin
Growth Hormone
Kisspeptin-10
Sexual Health
KPV (Alpha-MSH Fragment)
Healing & Recovery
Lactoferricin B
Immune
Larazotide
Healing & Recovery
Lentinan
Immune
Leuphasyl
Cosmetic
Leuprolide
Hormone Support
Liraglutide
Weight Management
Livagen
Anti-Aging
Lixisenatide
Weight Management
LL-37
Immune
Macimorelin
Growth Hormone
Magainin-2
Immune
Mazdutide
Weight Management
Melanotan-2
Cosmetic
MK-677 (Ibutamoren)
Growth Hormone
MOTS-c
Metabolic
Myristoyl Pentapeptide-17
Cosmetic
N-Acetyl Selank
Cognitive
N-Acetyl Semax Amidate
Cognitive
NAD+
Mitochondrial
Nafarelin
Hormone Support
Natriuretic Peptide (ANP)
Healing & Recovery
Nesiritide (BNP)
Healing & Recovery
Nisin
Immune
Noopept (Omberacetam)
Cognitive
Orforglipron
Weight Management
Ovagen
Anti-Aging
Oxytocin Acetate
Hormone Support
P21 (P021)
Cognitive
PACAP-38
Healing & Recovery
Palmitoyl Oligopeptide
Cosmetic
Palmitoyl Pentapeptide-4 (Matrixyl)
Cosmetic
Palmitoyl Tetrapeptide-7
Cosmetic
Palmitoyl Tripeptide-1
Cosmetic
Pancragen
Metabolic
PEG-MGF
Healing & Recovery
Pemvidutide
Weight Management
Pentadecapeptide (BPC Analog)
Healing & Recovery
Pidotimod
Immune
Pinealon
Cognitive
PNC-27
Immune
Polymyxin B
Immune
Pralmorelin (GHRP-2)
Growth Hormone
Pramlintide
Weight Management
Prostamax
Hormone Support
PT-141 (Bremelanotide)
Sexual Health
Relaxin-2 (Serelaxin)
Healing & Recovery
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Setmelanotide
Weight Management
SLU-PP-332
Metabolic
SM-130686
Growth Hormone
Snap-8
Cosmetic
SS-31 (Elamipretide)
Mitochondrial
Substance P Antagonists
Healing & Recovery
Survodutide
Weight Management
SYN-AKE
Cosmetic
Tabimorelin
Growth Hormone
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Testagen
Hormone Support
Thymalin
Immune
Thymopentin (TP-5)
Immune
Thymopoietin
Immune
Thymosin Alpha-1
Immune
Thymosin Beta-4
Healing & Recovery
Thymulin (FTS)
Immune
Thymulin Analog (PAT)
Healing & Recovery
Tirzepatide
Weight Management
Tripeptide-29
Cosmetic
Triptorelin
Hormone Support
Ularitide
Healing & Recovery
Urocortin
Healing & Recovery
Ventfort
Anti-Aging
Vesilute
Hormone Support
Vilon
Immune
VIP (Vasoactive Intestinal Peptide)
Healing & Recovery
Xenin-25
Metabolic
Ziconotide (Prialt)
Healing & Recovery
Total Peptides: 137
Back to Home

Tesamorelin

The only FDA-approved peptide specifically designed to melt away stubborn belly fat by telling your brain to release more growth hormone naturally—working with your body's own systems rather than replacing them [6].

Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards

Growth HormoneFDA approved for other use

Suggested dose

2 mg

Once dailyCycle: 12+ weeksOnset: Moderate (1-2 weeks)
26-38 minutesHalf-life
~100%Bioavailability(subcutaneous injection)
5135.86 g/molMolecular weight
Strong human trialsEvidence level

Compound profile

Tesamorelin scientific & efficacy data

Growth Hormone

Peptide profile

Visceral Fat Reduction9.6
Metabolic Health8.9
Natural GH Boost9.2

Strong human trials

Tesamorelin

2 mg (1.4 mg with Egrifta SV/WR F8 formulation) · Once daily

Molecular formula

C221H366N72O67S

Mol. weight
5135.86 g/mol
CAS number
218949-48-5
PubChem
16137828
Developed · 2000
Theratechnologies Research Team
Theratechnologies Inc.

Amino acid sequence

Trans-3-hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

Visceral Fat Reduction

FDA-approved with Phase 3 trial data showing 15-18% reduction in dangerous belly fat—among the strongest evidence for any fat-targeting peptide [1][6][7]

Metabolic Health

Significantly improves triglycerides, cholesterol ratios, and liver fat markers as visceral fat decreases [2][4]

Natural GH Boost

Increases IGF-1 levels by 100%+ while maintaining physiological feedback—works with your body's own systems [1][6]

Dosing

How much Tesamorelin do I take?

2 mg · once daily

26 weeks, continued long-term for sustained effect

2 mg

Once daily

Covers timing · dose-adjustment guidance.

TesamorelinOnce daily

How much peptide is in your bottle?

Look at the label on the vial. It’s the number next to the unit — like "5 mg". Labeled in IU? Switch the unit to IU.

Type a number to continue.
0

Suitability

Is Tesamorelin right for me?

Best for reducing visceral abdominal fat & improving metabolic health markers

Best for

People with Stubborn Visceral Fat

If you carry your weight around your midsection—the deep belly fat that wraps around your organs—tesamorelin is specifically designed for you. Unlike weight loss drugs, it targets visceral fat while preserving the normal subcutaneous fat that's healthy to have [5].

HIV Patients with Lipodystrophy

Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy—the abnormal fat accumulation in the belly that antiretroviral medications can cause [6]. It's the only treatment proven to help this condition, reducing both the physical and psychological burden [1][5].

Those Concerned About Metabolic Health

Visceral fat isn't just cosmetic—it's metabolically dangerous, linked to heart disease, diabetes, and inflammation [10][12]. By reducing visceral fat, tesamorelin also improves triglycerides, cholesterol ratios, and may help protect your liver from fatty liver disease [1][2][4].

Adults Wanting Natural GH Stimulation

Unlike synthetic growth hormone injections, tesamorelin works WITH your body's natural systems. It tells your pituitary to release more of YOUR OWN growth hormone, maintaining normal feedback loops and reducing the risks associated with supraphysiological GH levels [10].

Consider alternatives if

Reducing belly fat through other peptidesSermorelin, CJC-1295 + Ipamorelin, AOD-9604
Weight loss (general)Semaglutide, Tirzepatide, Lifestyle modifications
Increasing growth hormone naturallyGHRP-6, Ipamorelin, Sermorelin, MK-677

Do not use if

You have active cancer or a history of malignancy—growth hormone can potentially stimulate tumor growthYou have pituitary problems from surgery, radiation, or tumors affecting the hypothalamic-pituitary axisYou are pregnant or planning to become pregnantYou have a known allergy to tesamorelin or mannitol (a stabilizing ingredient)You have uncontrolled diabetes—tesamorelin can worsen glucose tolerance

Use with caution if

You have pre-diabetes or impaired glucose tolerance—monitor blood sugar closelyYou take medications that affect blood sugar like insulin or oral diabetes drugsYou have a history of carpal tunnel syndrome—GH elevation can worsen symptomsYou have fluid retention issues or heart problems—edema can occurYou take glucocorticoids (steroids)—they may reduce tesamorelin's effectivenessYou're over 65—less clinical data exists for elderly patients

Not sure?

Compare Tesamorelin with similar peptides to find the best fit for your goals.

Administration

How do I use Tesamorelin?

Subcutaneous injection

Route

Subcutaneous injection (just under the skin into fatty tissue)—this is the only approved administration route

Best sites

Abdomen (2 inches away from belly button)—the most common siteFront or outer thighRotate sites to prevent lipodystrophy at injection locations

Covers reconstitution · step-by-step technique · storage · a sample daily schedule.

Safety

Is Tesamorelin safe?

4 common side effects · 3 serious

Tesamorelin has a strong safety profile backed by FDA approval and multiple large Phase 3 clinical trials involving over 800 patients [1][6].

The most common issues are injection site reactions and the typical side effects of elevated growth hormone (joint pain, fluid retention) [6]. Glucose metabolism should be monitored as some patients experience increased blood sugar [6].

Long-term cardiovascular safety data is still being collected, which is why the FDA recommends reassessing treatment if visceral fat doesn't reduce [6].

Safety data comes from well-designed, placebo-controlled Phase 3 trials published in peer-reviewed journals and reviewed by the FDA [1][6]. Studies extended up to 52 weeks with safety monitoring [1]. This represents some of the strongest evidence available for any peptide therapy.

Less common

Carpal tunnel symptomsElevated blood glucose

These typically resolve with continued use or dose adjustment.

Common side effects · experienced by some users

  • Injection site reactions

    Redness, itching, pain, swelling, or bruising where you inject. This is the most frequently reported side effect, affecting up to 25-30% of users [6].

    Management: Rotate injection sites between left and right abdomen. Make sure the solution reaches room temperature before injecting. Apply a cool compress if needed. Most reactions resolve within a day or two.

  • Joint pain (arthralgia)

    Aching in joints, particularly knees, hips, or hands. This happens because increased growth hormone affects your connective tissues [14].

    Management: Often improves after the first few weeks as your body adjusts. Stay well-hydrated. If severe, discuss dose adjustment with your doctor. Over-the-counter pain relievers can help.

  • Muscle pain (myalgia)

    General muscle aches or soreness, similar to what you might feel after exercise [6].

    Management: Usually mild and transient. Gentle stretching and staying active can help. Should improve within the first month of treatment.

  • Peripheral edema

    Swelling in your hands, feet, or ankles due to fluid retention—a known effect of growth hormone [6].

    Management: Usually mild. Reduce salt intake and stay active. Elevate feet when resting. If swelling is significant or affects breathing, contact your doctor immediately.

Stop and seek help if

  • Severe allergic reaction occurs—stop immediately and seek emergency care
  • Visceral fat has not decreased after 3 months of treatment (per FDA guidance) [6]
  • Blood glucose becomes uncontrolled despite adjustments
  • Development of new or worsening malignancy [6]
  • Pregnancy occurs or is planned [6]
  • Intolerable side effects that don't resolve with dose adjustment

Tesamorelin is an FDA-approved prescription medication that should only be used under physician supervision. Never start, stop, or adjust your dose without consulting your prescribing healthcare provider. This information is educational and does not constitute medical advice.

With other peptides

  • Safe:CJC-1295 — Similar mechanism (GHRH pathway). Can be used together but may be redundant. Some practitioners alternate rather than combine.
  • Safe:Ipamorelin — Works on different receptor (GHRP). Can complement tesamorelin for enhanced GH release. Use at different times of day.
  • Safe:Sermorelin — Very similar mechanism (also GHRH analog). Generally not used together—choose one or the other.
  • Safe:BPC-157 — Different mechanism entirely (healing peptide). Safe to use together if addressing different goals.

With medications

  • Caution:Insulin — Tesamorelin can increase blood glucose, potentially requiring insulin dose adjustments. Monitor closely.
  • Caution:Oral diabetes medications — May need dose adjustment as tesamorelin affects glucose metabolism. Work with your endocrinologist.
  • Safe:Glucocorticoids (prednisone, etc.) — Steroids may reduce tesamorelin's effectiveness and counteract fat reduction benefits.
  • Caution:Growth hormone — Do not combine. Using both would be redundant and could cause excessive GH effects.

With supplements

  • Safe:Arginine — May have additive GH-releasing effects. Generally safe but probably unnecessary with tesamorelin.
  • Safe:Glucose disposal agents (berberine, etc.) — May help counteract tesamorelin's glucose-raising effects. Discuss with your doctor.
  • Safe:Fish oil — Safe to combine. May complement the triglyceride-lowering effects of tesamorelin.
  • Safe:Chromium — Safe. May help with blood sugar regulation.

Effectiveness

How do I know Tesamorelin is working?

Strong human trials · first signs weeks 1-2

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

FDA approved for other use

Onset of effects

Moderate

(1-2 weeks)

How it works

Your pituitary gland (a pea-sized gland at the base of your brain) releases growth hormone throughout the day, especially while you sleep.

As we age, this release decreases [13]. Tesamorelin is basically a messenger molecule that tells your pituitary to release more growth hormone naturally [1].

It's almost identical to the 44-amino-acid signal your hypothalamus already makes, but with a small chemical modification that makes it last longer in your body [6].

When growth hormone goes up, it signals your body to break down fat for energy—especially the dangerous visceral fat wrapped around your organs [1][5]. The beauty is that you're not injecting growth hormone itself; you're just amplifying your body's own system.

The deeper mechanism

Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminal tyrosine residue [6].

This modification protects the molecule from rapid degradation by dipeptidyl peptidase-4 (DPP-4), extending its half-life while preserving full receptor binding activity [8].

Upon subcutaneous injection, tesamorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary, activating adenylyl cyclase via Gs-coupled signaling [9]. This increases intracellular cAMP, which promotes growth hormone gene transcription and pulsatile GH secretion [9][10].

The elevated GH stimulates hepatic IGF-1 production and directly promotes lipolysis in adipose tissue, with preferential effects on visceral adipose tissue [3][5].

The mechanism for visceral fat selectivity may relate to differential expression of GH receptors and lipolytic enzymes between visceral and subcutaneous fat depots [15].

Unlike exogenous GH administration, tesamorelin maintains physiological feedback regulation through somatostatin, reducing the risk of sustained supraphysiological GH levels.

What to expect

  1. Weeks 1-2

    What you might notice

    • Injection site reactions as your body adjusts [6]
    • Possibly some joint stiffness or mild aching [6]
    • May feel some fluid retention in hands or feet [6]
    • No visible body composition changes yet

    What's normal

    • Mild injection site redness or itching that resolves in 1-2 days
    • Slight puffiness in extremities, especially in the morning
    • Initial adjustment period discomfort

    What's next

    • Continue with daily injections at consistent times
    • Track any side effects to discuss with your doctor
    • Side effects typically improve as your body adjusts
  2. Weeks 3-8

    What you might notice

    • Injection site reactions typically decrease significantly
    • IGF-1 levels rising on bloodwork (if tested) [3]
    • May notice clothes fitting slightly differently around waist
    • Energy levels may improve as GH levels optimize

    What's normal

    • Settling into the routine with manageable side effects
    • Subtle changes in how your midsection looks or feels
    • Better tolerance than the first couple weeks

    What's next

    • Continue consistent daily dosing
    • Most practitioners recommend imaging (CT or MRI) at baseline and 12-26 weeks
    • Monitor blood glucose at regular intervals
  3. Weeks 12-26

    What you might notice

    • Measurable reduction in visceral fat (15-18% average in clinical trials) [1]
    • Waist circumference decreasing noticeably
    • Improved triglyceride levels on bloodwork [1]
    • Better body image and reduced belly-related distress [1]

    What's normal

    • Significant visceral fat reduction visible on imaging [1]
    • Improved metabolic markers like triglycerides [1][2]
    • Stable weight overall (tesamorelin is weight-neutral) [11]

    What's next

    • Discuss continuation with your physician
    • Benefits are maintained with continued treatment [1]
    • Stopping treatment will cause visceral fat to return [5][7]
  4. Weeks 26-52 and beyond

    What you might notice

    • Continued maintenance of reduced visceral fat [1]
    • Sustained metabolic improvements
    • Possible continued incremental benefits
    • Long-term tolerance typically well-established [5]

    What's normal

    • Stable visceral fat reduction maintained at ~17-18% below baseline [1][7]
    • Steady IGF-1 levels within normal range
    • Manageable or resolved side effects

    What's next

    • Many patients continue indefinitely for maintenance
    • Regular monitoring of IGF-1 and glucose recommended
    • Reassess periodically with your healthcare provider

Signs it's working

Body Composition

  • Measurable decrease in waist circumference over 3-6 months
  • Reduction in visceral fat on CT or MRI imaging [1]
  • Clothes fitting looser around the midsection
  • Reduced belly appearance distress or improved body image [1]

Metabolic Markers

  • Decreased triglyceride levels on blood tests [1][2]
  • Improved cholesterol ratios (total cholesterol to HDL)
  • IGF-1 levels elevated into upper normal range
  • Stable or improved liver function tests

Subjective Well-Being

  • Feeling less distressed about belly appearance [1]
  • Improved self-image regarding body shape
  • Better energy levels throughout the day
  • Sense of metabolic health improvement

Not seeing results? Common reasons

  • Not injecting on an empty stomach—food can interfere with absorption and effectiveness
  • Inconsistent daily dosing—tesamorelin works best with consistent daily administration
  • Insufficient treatment duration—real visceral fat reduction takes 12-26 weeks to manifest [1]
  • Unrealistic expectations—tesamorelin reduces visceral fat, not overall weight [5]
  • Poor injection technique—ensure proper subcutaneous delivery, not intramuscular
  • Confounding medications like high-dose steroids that counteract the effects

Key research

2010[1]
“Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials”Falutz J, Mamputu JC, Potvin D, et al.Finding: In this combined analysis of over 800 HIV patients, tesamorelin reduced visceral fat by an average of 15.4% compared to placebo at 26 weeks. The reduction was maintained at 52 weeks in those who continued treatment. It also improved triglycerides by 12% and significantly improved how patients felt about their belly appearance.View study
2012[2]
“Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin”Stanley TL, Falutz J, Marsolais C, et al.Finding: Patients who achieved at least 8% reduction in visceral fat (called 'responders') experienced significantly greater improvements in triglycerides, glucose control, and adiponectin levels compared to non-responders. This shows that the metabolic benefits directly correlate with how much visceral fat you lose.View study
2012[3]
“Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults”Baker LD, Barsness SM, Borson S, et al.Finding: In a 20-week trial with 152 adults (some with mild cognitive impairment), tesamorelin improved executive function and showed a trend toward better verbal memory. IGF-1 levels increased 117% and body fat decreased 7.4%. This suggests tesamorelin may have brain health benefits beyond just fat reduction.View study
2019[4]
“Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial”Stanley TL, Fourman LT, Feldpausch MN, et al.Finding: In people with HIV and fatty liver disease, tesamorelin reduced liver fat by 37% relative to placebo over 12 months. Remarkably, 35% of tesamorelin patients achieved liver fat levels below 5% (essentially normal) compared to only 4% on placebo. This opens up potential new uses for liver health.View study
2011[5]
“Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy”Dhillon SFinding: This comprehensive review confirmed tesamorelin's effectiveness and safety profile. It noted that while visceral fat reduces significantly, subcutaneous fat stays stable—an important distinction because subcutaneous fat is metabolically healthier. Side effects were manageable and serious events occurred in less than 4% of patients.View study
2019[6]
“EGRIFTA SV (tesamorelin for injection) Prescribing Information”Theratechnologies Inc. / U.S. FDAView study
2010[7]
“Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension”Falutz J, Potvin D, Mamputu JC, et al.Finding: In this 12-month trial of 404 HIV-infected patients, visceral fat fell 10.9% on tesamorelin versus 0.6% on placebo over the first 6 months, and was about 18% below baseline in patients who continued the drug for 12 months. Patients re-randomized from tesamorelin to placebo rapidly lost the visceral fat reduction they had gained. No change in glucose parameters was observed.View study
2007[8]
“Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue”Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil PFinding: Adding a trans-3-hexenoyl group to the first amino acid of GHRH(1-44) made the peptide resistant to dipeptidyl aminopeptidase-IV breakdown, slowing its degradation in rat, dog and human plasma and prolonging how long it stayed in circulation. The modified peptide still raised growth hormone and IGF-1 in pigs, rats and dogs. Apparent elimination half-life in dogs was 21 to 45 minutes.View study
2025[9]
“Growth hormone-releasing hormone receptor (GHRH-R) and its signaling”Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AVFinding: This review describes GHRH binding to the pituitary GHRH receptor, a G protein-coupled receptor expressed mainly on somatotroph cells of the pituitary. Receptor activation raises intracellular cAMP, and the resulting signaling phosphorylates CREB, which with its coactivators p300 and CREB-binding protein increases growth hormone gene transcription.View study
2015[10]
“Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies”Stanley TL, Grinspoon SKFinding: This review of human studies reports that GHRH treatment increases the body's own basal and pulsatile growth hormone secretion without changing pulse frequency, and that giving GHRH preserves the normal IGF-1 negative feedback on pituitary GH release, with IGF-1 monitored to keep levels in the physiological range. It also notes that increased visceral fat and reduced GH each contribute independently to dyslipidemia, systemic inflammation, and cardiovascular risk, and that GHRH treatment reduces visceral fat and improves these markers.View study
2012[11]
“Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial”Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SKFinding: In obese adults without HIV who had reduced growth hormone secretion, tesamorelin reduced visceral fat (treatment effect -35 cm2) while body weight did not differ significantly from placebo (0.1 kg vs 0.9 kg, P = 0.52). The authors note that weight stayed flat because fat mass fell and lean mass rose by similar amounts.View study
2019[12]
“Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement”Neeland IJ, Ross R, Despres JP, et al.Finding: This joint position statement summarises three decades of epidemiological evidence that visceral adipose tissue, measured by CT or MRI, is an independent risk marker for cardiovascular and metabolic illness and death, and reviews visceral and ectopic fat as risk factors for type 2 diabetes, atherosclerosis, and cardiovascular disease.View study
2019[13]
“The enigmatic role of growth hormone in age-related diseases, cognition, and longevity”Colon G, Saccon T, Schneider A, et al.Finding: This review of growth hormone and aging states that GH levels fall gradually after puberty, and that after the third decade of life the decrease is about 14% per decade.View study
2013[14]
“Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement”Reed ML, Merriam GR, Kargi AYFinding: This review reports that the most common side effects of growth hormone treatment in adults come from fluid retention, and lists peripheral edema, arthralgia, carpal tunnel syndrome, paresthesias, and worsening glucose tolerance among them. It also notes that these effects became less frequent once dosing moved from high weight-based regimens to low starting doses titrated upward, and that the side effect profile of replacement doses does not apply to supraphysiologic dosing.View study
2011[15]
“Human growth hormone receptor (GHR) expression in obesity: I. GHR mRNA expression in omental and subcutaneous adipose tissues of obese women”Erman A, Veilleux A, Tchernof A, Goodyer CGFinding: Growth hormone receptor mRNA was measured in omental (visceral) and subcutaneous fat from 55 women across the range of body weight. Receptor expression was 2 to 3 fold lower in obese than lean women in both depots, and in lean women receptor levels were higher in omental than in subcutaneous fat, a depot difference that disappeared with obesity.View study
2000[16]
“Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men”Hashimoto Y, Kamioka T, Hosaka M, Mabuchi K, Mizuchi A, Shimazaki Y, Tsunoo M, Tanaka TFinding: Healthy men were given injections of the 20K isoform of human growth hormone. Their own 22K growth hormone secretion was markedly suppressed in a time-dependent manner, showing that injected growth hormone shuts down the pituitary's own GH release.View study

Clinical trials

Tesamorelin tested in people

23 registered studies, 3 still enrolling.

23registered studies
3recruiting now
4phase 3 or 4
9with published results

By phase

Phase 29
Phase 12
Phase 32
Phase 42
No phase8

A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.

What kind of research

Gave the drug20
Records only3

About 1,503 people took part in the studies that actually administered Tesamorelin. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.

Most recent

  • NCT07481734Phase 2Recruiting120 enrolled

    Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

    Hudson Biotech

  • NCT06554717Phase 2Recruiting100 enrolled

    Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

    Massachusetts General Hospital

  • NCT03826160Completed23 enrolled

    Growth Hormone Dynamics and Cardiac Steatosis in HIV

    Massachusetts General Hospital

See all 23 trials for Tesamorelin

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Tesamorelin is named as an intervention; studies that only mention it in passing are not.

Questions

Frequently asked about Tesamorelin

Will tesamorelin help me lose weight?

Tesamorelin is 'weight neutral'—you probably won't see the number on the scale change much [11]. What changes is your body composition: visceral fat goes down significantly while other tissues stay stable [1][5]. You might drop a pants size without losing pounds because visceral fat is being replaced by nothing (not muscle). If overall weight loss is your goal, consider GLP-1 medications like semaglutide instead.

How is tesamorelin different from growth hormone injections?

Big difference! Growth hormone injections give you external GH that can suppress your own production and cause supraphysiological levels [14][16]. Tesamorelin tells your pituitary to release more of YOUR OWN growth hormone, maintaining natural feedback loops and pulsatile release patterns [10]. It's like turning up the volume on your natural system rather than replacing it with a synthetic one.

Why is it only FDA-approved for HIV patients?

HIV-associated lipodystrophy (abnormal fat distribution from antiretroviral drugs) was the specific condition Theratechnologies targeted for approval because there was no treatment for it [6]. The FDA approval process is disease-specific. However, the mechanism works in anyone with excess visceral fat—that's why physicians prescribe it off-label for non-HIV patients with similar issues [3].

What happens when I stop taking tesamorelin?

Unfortunately, the visceral fat comes back. Clinical trials showed that patients who switched from tesamorelin to placebo regained their visceral fat within 26 weeks [5][7]. This means tesamorelin is typically a long-term or indefinite treatment if you want to maintain the benefits. Think of it like blood pressure medication—it works while you take it.

Will tesamorelin affect my blood sugar?

It can, which is why monitoring is important. Growth hormone has anti-insulin effects, so fasting glucose and HbA1c can increase in some patients [6]. Clinical trials showed that most patients had only mild changes that didn't reach clinical significance, but if you have pre-diabetes or diabetes, you need closer monitoring and possible medication adjustments [1][7].

Can I use tesamorelin for bodybuilding?

While tesamorelin does increase GH and IGF-1, it's not ideal for bodybuilding purposes [3]. It's specifically designed to reduce visceral fat, not build muscle. The GH increase is more modest than what bodybuilders typically seek with other secretagogues or direct GH. If muscle growth is your primary goal, other peptide combinations might be more appropriate.

How long until I see results?

Most visible and measurable changes occur between weeks 12-26 [1]. You might notice subtle changes earlier (clothes fitting differently, less bloating), but the significant 15-18% reduction in visceral fat that clinical trials demonstrated takes several months of consistent daily use [1]. Patience and consistency are key.

Is tesamorelin safe to use long-term?

Clinical trials studied tesamorelin for up to 52 weeks and found it well-tolerated with manageable side effects [1][5]. Many patients use it indefinitely since stopping causes visceral fat to return [5][7]. However, long-term cardiovascular safety data is still being collected, which is why the FDA recommends reassessing if you don't see visceral fat reduction [6]. Regular monitoring of IGF-1 and glucose is recommended for extended use [6].

Further reading

Tesamorelin history & related research

History · since 1995

The Canadian Peptide That Gave HIV Patients Their Bodies Back

When AIDS drugs saved lives but stole patients' appearances, a small Montreal company created a solution. Tesamorelin became the first and only treatment for a condition no one talked about — the fat redistribution that made HIV survivors look sick even when they weren't.

Read the full history of Tesamorelin

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Tesamorelin, on one page.

Medical disclaimer

Tesamorelin is FDA approved for one or more other indications, but not for every use described here. Uses outside its approved labeling are off-label and should only be considered under the supervision of a qualified healthcare provider. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 9, 2026